Ronan J. Kelly, MD, MBA / Siva Raja, MD, PhD, FACS - Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer: The Latest Evidence and Implications for Thoracic Surgeons and the Multidisciplinary Care Team

59:11
 
シェア
 

Manage episode 295756266 series 103583
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to PeerView.com/PSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As key members of the interdisciplinary care team, thoracic surgeons play an essential role in collaborating and coordinating with their colleagues from other specialties to assess and manage patients with esophageal/GEJ cancer and determine the most appropriate treatment plans based on new evidence inclusive of local and systemic treatment modalities. Thoracic surgeons must also engage patients in shared decision-making to select appropriate treatment according to stage, tumor characteristics, and patient values and preferences, among other key factors. This activity will provide a comprehensive, practically oriented, multidisciplinary overview on the expanding role of immunotherapy in esophageal and GEJ cancer. The experts discuss essential evidence supporting clinical decisions and offer practical guidance on key clinical issues concerning the continued integration of immunotherapy into individualized management plans for patients with esophageal/GEJ cancer. Upon completion of this accredited CE activity, participants should be better able to: Summarize the biologic rationale for the use of immune checkpoint inhibitors in the multimodal treatment of locally advanced and early-stage esophageal/GEJ cancer, Appraise the latest safety and efficacy evidence and guideline recommendations on the use of immune checkpoint inhibitors in patients with locally advanced or early-stage esophageal/GEJ cancer, Implement a collaborative care model among surgical, medical, and radiation oncology specialists and the greater multidisciplinary team to integrate immunotherapy into multimodal treatment plans for eligible patients with locally advanced or early-stage esophageal/GEJ cancer based on recent evidence, patient- and disease-related factors, and guideline recommendations.

84 つのエピソード